NOCIL Q4 FY26 PAT Rs 17 Cr, Volume Grows 7%
NOCIL Limited reported a 5% sequential increase in revenue to Rs 330 crore for Q4 FY26, driven by a 7% volume rise. Profit after tax improved to Rs 17 crore from Rs 9 crore in the preceding quarter. Despite pricing pressures from imports and higher costs, the company anticipates sustained volume growth and has implemented price hikes to mitigate raw material inflation.
*this image is generated using AI for illustrative purposes only.
NOCIL Limited held its earnings call on May 8, 2026, to discuss the operational and financial performance for the quarter and year ended March 31, 2026. The company reported revenue from operations of Rs.330 crores for Q4 FY26, reflecting a sequential growth of 5% and a volume increase of 7%. For the full year FY26, revenue stood at Rs.1,303 crores compared to Rs.1,393 crores in FY25.
Operational Performance
Management attributed the volume growth to improved demand following the implementation of GST 2.0 and strengthened customer partnerships. Domestic volumes witnessed single-digit growth, while international markets also posted steady gains. However, realizations remained under pressure due to the dumping of lower-priced imports. The company stated it is maintaining an optimal balance between price and volume to navigate the evolving global environment.
Financial Highlights
Profit after tax (PAT) for Q4 FY26 stood at Rs.17 crores, compared to Rs.9 crores in the previous quarter. For the full year, PAT was Rs.56 crores against Rs.103 crores in FY25. The decline in profitability was attributed to narrowed spreads due to the Free Trade Agreement (FTA) regime wiping out basic duty protection on certain products, as well as higher utility and maintenance costs during the quarter.
| Metric | Q4 FY26 | Q3 FY26 | FY26 | FY25 |
|---|---|---|---|---|
| Revenue from Operations (Rs. Cr): | 330 | 316 | 1,303 | 1,393 |
| PAT (Rs. Cr): | 17 | 9 | 56 | 103 |
Strategic Updates
The Director General of Trade Remedies (DGTR) recommended positive final findings in March 2026 regarding antidumping petitions for the antioxidant TDQ and Sulphenamides (CBS and NS). These recommendations are subject to central government approvals. On the capex front, the TDQ capex at Dahej has been completed with trial production commenced. The total capex incurred was less than Rs.250 crores. Additionally, the company announced a new capex of Rs.130 crores on March 16, 2026, for a specialty facility expected to be completed by H1 FY28.
Outlook
Looking ahead, NOCIL expects the positive volume momentum to sustain. The company has revised prices upwards for the non-contractual business and from the current quarter for contractual business to address significant raw material price increases. Management remains focused on cost efficiency initiatives, product mix enhancement, and geographical expansion to drive long-term growth.
Historical Stock Returns for NOCIL
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.64% | -3.00% | -9.23% | -3.04% | -11.73% | -20.79% |
How quickly could the central government's antidumping duty approvals on Sulphenamides and TDQ translate into meaningful margin recovery, and what is the realistic upside to EBITDA margins if all pending petitions receive favorable rulings?
With tire manufacturers typically requiring 6–8 months for approval cycles, how might NOCIL's new TDQ capacity ramp-up timeline be affected if global tire demand softens due to macroeconomic headwinds or EV adoption shifts?
Given that 65–70% of NOCIL's business is contractual, how will the lag in passing through raw material price increases to contractual customers impact margin trajectory in H1 FY27 compared to the non-contractual segment?
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
